Terapia insulinica e inerzia. Intelligenza artificiale come driver di cambiamento | 3-4 Febbraio 2023 Share Post navigation Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trialSGLT2i come utile terapia aggiuntiva nel diabete HNF4A-MODY: case report
